Unlike other brands that release their ads days or weeks ahead of the Big Game, Novartis is waiting to unveil its commercial ...

The Swiss pharmaceutical company has set a high bar for any potential obesity-treatment acquisition as it scans the market ...

Initially launching in Germany, the app will soon be available in the UK, Australia, Canada, and other markets.

AbbVie’s Skyrizi was responsible for the highest TV advertising outlay in pharma in most months of 2024, but 2025 is starting ...

Novartis on Friday posted adjusted net income well above analyst estimates as sales of established heart failure drug ...

CEO Vas Narasimhan told the Wall Street Journal the company is searching for next-generation obesity drug candidates, even if ...

Novartis has become the latest drugmaker to get in trouble over an employee’s LinkedIn likes. The U.K. | Novartis has become ...

Novartis was among the most prolific pharma dealmakers in 2024, a trend that it expects to continue with more bolt-on deals ...

While the political pushback to ESG continues to grow in the U.S., there was little sign in Davos last week that business ...

Novartis AG's ( VTX:NOVN ) dividend will be increasing from last year's payment of the same period to $3.50 on 13th ...

The pharma major beat analysts’ expectations in the fourth quarter of 2024, despite looming competition for its top heart ...

In a report released today, James Quigley from Goldman Sachs maintained a Hold rating on Novartis AG (NOVN – Research Report), with a price ...